The DOI matches its Crossref record; 316 of the 316 references it cites were found in a registry or an index.
The Hippo pathway in cancer: YAP/TAZ and TEAD as therapeutic targets in cancer
Open accessAbstract
Tumorigenesis is a highly complex process, involving many interrelated and cross-acting signalling pathways. One such pathway that has garnered much attention in the field of cancer research over the last decade is the Hippo signalling pathway. Consisting of two antagonistic modules, the pathway plays an integral role in both tumour suppressive and oncogenic processes, generally via regulation of a diverse set of genes involved in a range of biological functions. This review discusses the history of the pathway within the context of cancer and explores some of the most recent discoveries as to how this critical transducer of cellular signalling can influence cancer progression. A special focus is on the various recent efforts to therapeutically target the key effectors of the pathway in both preclinical and clinical settings.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–316 of 316
Picco, G., Chen, E. D., García‐Alonso, L., Behan, F. M., Gonçalves, E., Bignell, G. R., Matchan, A., Fu, B., Banerjee, R., Anderson, E., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-09940-1 · Cited by 131
Small GTP-binding protein-coupled receptors
Bhattacharya, M., Babwah, A. V., & Ferguson, S. S. G. (2004) · Biochemical Society Transactions · doi:10.1042/bst0321040 · Cited by 130
NUAK2 is a critical YAP target in liver cancer
Yuan, W.-C., Pepe-Mooney, B. J., Galli, G. G., Dill, M. T., Huang, H., Hao, M., Wang, Y., Liang, H., Calogero, R., & Camargo, F. D. (2018) · Nature Communications · doi:10.1038/s41467-018-07394-5 · Cited by 130
Super-Enhancers at the Nanog Locus Differentially Regulate Neighboring Pluripotency-Associated Genes
Blinka, S. M., Reimer, M. H., Pulakanti, K., & Rao, S. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.09.002 · Cited by 129
Bian, D., Mahanivong, C., Yu, J., Frisch, S. M., Pan, Z. K., Ye, R. D., & Huang, S. (2005) · Oncogene · doi:10.1038/sj.onc.1209261 · Cited by 128
MST1 Suppresses Pancreatic Cancer Progression via ROS-Induced Pyroptosis
Cui, J., Zhou, Z., Yang, H., Jiao, F., Li, N., Gao, Y., Wang, L., Chen, J., & Quan, M. (2019) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-18-0910 · Cited by 126
Yang, S., Zhang, L., Liu, M., Chong, R., Ding, S., Chen, Y., & Dong, J. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-2049 · Cited by 123
He, L., Pratt, H., Gao, M., Wei, F., Weng, Z., & Struhl, K. (2021) · eLife · doi:10.7554/elife.67312 · Cited by 122
Abali, G. K., Alptekin, A., Lewis, M. S., Garraway, I. P., & Cinar, B. (2015) · Nature Communications · doi:10.1038/ncomms9126 · Cited by 122
STRIPAK integrates upstream signals to initiate the Hippo kinase cascade
Chen, R., Xie, R., Meng, Z., Ma, S., & Guan, K. (2019) · Nature Cell Biology · doi:10.1038/s41556-019-0426-y · Cited by 122
Sabra, H., Brunner, M., Mandati, V., Wehrle‐Haller, B., Lallemand, D., Ribba, A., Chevalier, G., Guardiola, P., Block, M. R., & Bouvard, D. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.m117.808063 · Cited by 121
Tumor suppressor p53 restricts Ras stimulation of RhoA and cancer cell motility
Xia, M., & Land, H. (2007) · Nature Structural & Molecular Biology · doi:10.1038/nsmb1208 · Cited by 120
Yap regulates glucose utilization and sustains nucleotide synthesis to enable organ growth
Cox, A. G., Tsomides, A., Yimlamai, D., Hwang, K. L., Miesfeld, J. B., Galli, G. G., Fowl, B. H., Fort, M. W., Kimberly, Y., Sullivan, M. R., et al. (2018) · The EMBO Journal · doi:10.15252/embj.2018100294 · Cited by 119
Zhou, Y. M., Wang, Y., Zhou, W., Chen, T., Wu, Q., Chutturghoon, V. K., Lin, B., Geng, L., Yang, Z., Zhou, L., et al. (2019) · Cancer Cell International · doi:10.1186/s12935-019-0898-7 · Cited by 118
GPCR-Hippo Signaling in Cancer
Luo, J., & Yu, F. (2019) · Cells · doi:10.3390/cells8050426 · Cited by 114
Hippo signalling during development
Davis, J. R., & Tapon, N. (2019) · Development · doi:10.1242/dev.167106 · Cited by 113
Pajtler, K. W., Wei, Y., Okonechnikov, K., Silva, P. B. G., Vouri, M., Zhang, L., Brabetz, S., Sieber, L., Gulley, M., Mauermann, M., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-11884-5 · Cited by 110
Chiara, G. D., Gervasoni, F., Fakiola, M., Godano, C., D’Oria, C., Azzolin, L., Bonnal, R. J. P., Moreni, G., Drufuca, L., Rossetti, G., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-22544-y · Cited by 109
Dasari, V. R., Mazack, V., Feng, W., Nash, J. D., Carey, D. J., & Gogoi, R. P. (2017) · Oncotarget · doi:10.18632/oncotarget.15614 · Cited by 108
A Potential Role of YAP/TAZ in the Interplay Between Metastasis and Metabolic Alterations
Yamaguchi, H., & Taouk, G. M. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00928 · Cited by 107
Gaffney, C. J., Oka, T., Mazack, V., Hilman, D., Gat, U., Muramatsu, T., Inazawa, J., Golden, A. M., Carey, D. J., Farooq, A., et al. (2012) · Gene · doi:10.1016/j.gene.2012.08.025 · Cited by 104
STRIPAK complexes in cell signaling and cancer
Shi, Z., Jiao, S., & Zhou, Z. (2016) · Oncogene · doi:10.1038/onc.2016.9 · Cited by 103
Chen, M., Towers, L. N., & O’Connor, K. L. (2007) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00400.2006 · Cited by 98
Knight, J. F., Shepherd, C. J., Rizzo, S., Brewer, D. S., Jhavar, S. G., Dodson, A. R., Cooper, C. S., Eeles, R. A., Falconer, A., Kovács, G., et al. (2008) · British Journal of Cancer · doi:10.1038/sj.bjc.6604774 · Cited by 97
Zhang, W., Gao, Y., Li, F., Tong, X., Ren, Y., Han, X., Yao, S., Long, F., Yang, Z., Fan, H., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-3396 · Cited by 96
Zhao, Y., Khanal, P., Savage, P. B., She, Y., Cyr, T. D., & Yang, X. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-2712 · Cited by 96
Rho GTPase-dependent transformation by G protein-coupled receptors
Whitehead, I. P., Zohn, I. E., & Der, C. J. (2001) · Oncogene · doi:10.1038/sj.onc.1204188 · Cited by 96
Kang, J., Jeong, S., Shin, D. W., Cho, M. H., Cho, J. H., & Kim, J. (2020) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2020.08.021 · Cited by 95
Nuclear TAZ expression associates with the triple-negative phenotype in breast cancer
Díaz‐Martín, J., López‐García, M. Á., Romero‐Pérez, L., Atienza-Amores, M. R., Pecero, M. L., Castilla, M. Á., Biscuola, M., Santón, A., & Palacios, J. (2015) · Endocrine Related Cancer · doi:10.1530/erc-14-0456 · Cited by 94
O’Brien, A. J., Villani, L. A., Broadfield, L. A., Houde, V. P., Galić, S., Blandino, G., Kemp, B. E., Tsakiridis, T. K., Muti, P. C., & Steinberg, G. R. (2015) · Biochemical Journal · doi:10.1042/bj20150122 · Cited by 91
Inactivation of Merlin in malignant mesothelioma cells and the Hippo signaling cascade dysregulation
Sekido, Y. (2011) · Pathology International · doi:10.1111/j.1440-1827.2011.02666.x · Cited by 91
Targeting the Hippo Pathway for Breast Cancer Therapy
Wu, L., & Yang, X. (2018) · Cancers · doi:10.3390/cancers10110422 · Cited by 91
Smith, S. A., Sessions, R. B., Shoemark, D. K., Williams, C., Ebrahimighaei, R., McNeill, M. C., Crump, M. P., McKay, T. R., Harris, G., Newby, A. C., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b01402 · Cited by 91
The Hippo Pathway in Prostate Cancer
Salem, O., & Hansen, C. G. (2019) · Cells · doi:10.3390/cells8040370 · Cited by 90
Self-citationAn Integrative Analysis of the Tumorigenic Role of TAZ in Human Non–Small Cell Lung Cancer
Noguchi, S. F., Saito, A., Horie, M., Mikami, Y., Suzuki, H. I., Morishita, Y., Ohshima, M., Abiko, Y., Mattsson, J. S. M., König, H., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-3328 · Cited by 89
Targeting the Hippo Signaling Pathway for Tissue Regeneration and Cancer Therapy
Juan, W. C., & Hong, W. (2016) · Genes · doi:10.3390/genes7090055 · Cited by 89
Cell contact and Nf2/Merlin-dependent regulation of TEAD palmitoylation and activity
Kim, N.-G., & Gumbiner, B. (2019) · Proceedings of the National Academy of Sciences of the United States of America · doi:10.1073/pnas.1819400116 · Cited by 89
Nuclear localization and pro‐apoptotic signaling of YAP2 require intact PDZ‐binding motif
Oka, T., & Sudol, M. (2009) · Genes to Cells · doi:10.1111/j.1365-2443.2009.01292.x · Cited by 87
Kaposi sarcoma-associated herpesvirus promotes tumorigenesis by modulating the Hippo pathway
Liu, G., Yu, F., Kim, Y. C., Meng, Z., Naipauer, J., Looney, D. J., Liu, X., Gutkind, J. S., Mesri, E. A., & Guan, K.-L. (2014) · Oncogene · doi:10.1038/onc.2014.281 · Cited by 86
The regulation of Yorkie, YAP and TAZ: new insights into the Hippo pathway
Manning, S. A., Kroeger, B., & Harvey, K. F. (2020) · Development · doi:10.1242/dev.179069 · Cited by 86
TEAD–YAP Interaction Inhibitors and MDM2 Binders from DNA‐Encoded Indole‐Focused Ugi Peptidomimetics
Kunig, V. B. K., Potowski, M., Akbarzadeh, M., Škopić, M. K., Smith, D. D. S., Arendt, L., Dormuth, I., Adihou, H., Andlovic, B., Karataş, H., et al. (2020) · Angewandte Chemie International Edition · doi:10.1002/anie.202006280 · Cited by 86
Hippo pathway inhibition by blocking the YAP/TAZ–TEAD interface: a patent review
Crawford, J. J., Bronner, S. M., & Zbieg, J. R. (2018) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2018.1549226 · Cited by 85
Kitagawa, M. (2007) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2007.07.129 · Cited by 84
Fukami, M., Wada, Y. S., Okada, M., Kato, F., Katsumata, N., Baba, T., Morohashi, K.-I., Laporte, J., Kitagawa, M., & Ogata, T. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m703289200 · Cited by 84
Szulzewsky, F., Arora, S., Hoellerbauer, P., King, C., Nathan, E., Chan, M., Cimino, P. J., Ozawa, T., Kawauchi, D., Pajtler, K. W., et al. (2020) · Genes & Development · doi:10.1101/gad.338681.120 · Cited by 83
Hippo Pathway in Mammalian Adaptive Immune System
Yamauchi, T., & Moroishi, T. (2019) · Cells · doi:10.3390/cells8050398 · Cited by 82
TAZ Protein Accumulation Is Negatively Regulated by YAP Abundance in Mammalian Cells
Finch‐Edmondson, M., Strauss, R. P., Passman, A. M., Sudol, M., Yeoh, G. C., & Callus, B. A. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.692285 · Cited by 81
Jiang, N., Hjorth-Jensen, K., Hekmat, O., Iglesias‐Gato, D., Kruse, T., Wang, C., Wei, W., Ke, B., Yan, B., Niu, Y., et al. (2014) · Oncogene · doi:10.1038/onc.2014.206 · Cited by 78
WW domain interactions regulate the Hippo tumor suppressor pathway
Salah, Z., & Aqeilan, R. I. (2011) · Cell Death and Disease · doi:10.1038/cddis.2011.53 · Cited by 78
YAP1-fusions in pediatric NF2-wildtype meningioma
Sievers, P., Chiang, J., Schrimpf, D., Stichel, D., Paramasivam, N., Sill, M., Gayden, T., Casalini, B., Reuß, D., Dalton, J., et al. (2019) · Acta Neuropathologica · doi:10.1007/s00401-019-02095-9 · Cited by 78
Sun, X., Ren, Z., Cun, Y., Zhao, C., Huang, X., Zhou, J., Hu, R., Su, X., Ji, L., Li, P., et al. (2020) · Nucleic Acids Research · doi:10.1093/nar/gkaa482 · Cited by 76
YAP1 oncogene is a context-specific driver for pancreatic ductal adenocarcinoma
Tu, B., Yao, J., Ferri-Borgogno, S., Zhao, J., Chen, S., Wang, Q., Yan, L., Zhou, X., Zhu, C., Bang, S., et al. (2019) · JCI Insight · doi:10.1172/jci.insight.130811 · Cited by 75
Seavey, C. N., Pobbati, A. V., Hallett, A., Ma, S., REYNOLDS, J. P., Kanai, R., Lamar, J. M., & Rubin, B. P. (2021) · Genes & Development · doi:10.1101/gad.348220.120 · Cited by 70
EGFR Regulates the Hippo pathway by promoting the tyrosine phosphorylation of MOB1
Ando, T., Arang, N., Wang, Z., Costea, D. E., Feng, X., Goto, Y., Izumi, H., Gilardi, M., Ando, K., & Gutkind, J. S. (2021) · Communications Biology · doi:10.1038/s42003-021-02744-4 · Cited by 70
Py2T Murine Breast Cancer Cells, a Versatile Model of TGFβ-Induced EMT In Vitro and In Vivo
Waldmeier, L., Meyer‐Schaller, N., Diepenbruck, M., & Christofori, G. (2012) · PLoS ONE · doi:10.1371/journal.pone.0048651 · Cited by 69
Song, Q., Mao, B., Cheng, J., Gao, Y., Jiang, K., Chen, J., Yuan, Z., & Meng, S. (2015) · PLoS ONE · doi:10.1371/journal.pone.0120790 · Cited by 69
The Hippo pathway modulates resistance to BET proteins inhibitors in lung cancer cells
Gobbi, G., Donati, B., Do Valle, I. F., Reggiani, F., Torricelli, F., Remondini, D., Castellani, G., Ambrosetti, D. C., Ciarrocchi, A., & Sancisi, V. (2019) · Oncogene · doi:10.1038/s41388-019-0924-1 · Cited by 69
Kandasamy, S., Adhikary, G., Rorke, E. A., Friedberg, J. S., Mickle, M. B., Alexander, H. R., & Eckert, R. L. (2019) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-19-0914 · Cited by 67
Yu, O. M., Benitez, J. A., Plouffe, S. W., Ryback, D., Klein, A., Smith, J., Greenbaum, J., Delatte, B., Rao, A., Guan, K.-L., et al. (2018) · Oncogene · doi:10.1038/s41388-018-0301-5 · Cited by 62
Harms, P. W., Hovelson, D. H., Cani, A. K., Omata, K., Haller, M. J., Wang, M. L., Arps, D. P., Patel, R. M., Fullen, D. R., Wang, M., et al. (2016) · Human Pathology · doi:10.1016/j.humpath.2015.12.015 · Cited by 60
Salcedo, M. T., Zerón-Medina-Cuairán, J., Hernández‐Losa, J., Macarulla, T. M., Balsells, J., Merino, X., Allende, H., Tabernero, J. M., & y Cajal, S. R. (2017) · Pancreas · doi:10.1097/mpa.0000000000000867 · Cited by 60
Li, J., Li, Z., Wu, Y., Wang, Y., Wang, D., Zhang, W., Yuan, H., Ye, J., Song, X., Yang, J., et al. (2019) · Cell Death and Disease · doi:10.1038/s41419-019-1838-0 · Cited by 60
Bouvier, C., Macagno, N., Nguyen, Q. P., Loundou, A., Jiguet‐Jiglaire, C., Gentet, J., Jouve, J.-L., Rochwerger, A., Mattei, J.-C., Bouvard, D., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.11876 · Cited by 59
MAP4K Interactome Reveals STRN4 as a Key STRIPAK Complex Component in Hippo Pathway Regulation
Seo, G., Han, H., Vargas, R. E., Yang, B., Li, X., & Wang, W. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.107860 · Cited by 59
Bellizzi, A., Mangia, A., Chiriatti, A., Petroni, S., Quaranta, M., Schittulli, F., Malfettone, A., Cardone, R. A., Paradiso, A., & Reshkin, S. J. (2008) · International Journal of Molecular Medicine · doi:10.3892/ijmm.22.1.25 · Cited by 57
Identification of the kinase STK25 as an upstream activator of LATS signaling
Lim, S., Hermance, N. M., Mudianto, T., Mustaly, H. M., Mauricio, I. P. M., Vittoria, M. A., Quinton, R. J., Howell, B. W., Cornils, H., Manning, A. L., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-09597-w · Cited by 56
Faried, A., Faried, L. S., Usman, N., Kato, H., & Kuwano, H. (2007) · Annals of Surgical Oncology · doi:10.1245/s10434-007-9562-x · Cited by 55
Zhang, W., Li, J., Wu, Y., Ge, H., Song, Y., Wang, D., Yuan, H., Jiang, H., Wang, Y., & Cheng, J. (2018) · Cancer Cell International · doi:10.1186/s12935-018-0675-z · Cited by 55
The Role and Clinical Significance of Yes-Associated Protein 1 in Human Osteosarcoma
Zhang, Y.-H., Li, B., Shen, L., Shen, Y., & Chen, X. (2013) · International Journal of Immunopathology and Pharmacology · doi:10.1177/039463201302600115 · Cited by 54
Repression of YAP by NCTD disrupts NSCLC progression
Guo, J., Wu, Y., Yang, L., Du, J., Gong, K., Chen, W., Dai, J., Li, X., & Xi, S. (2016) · Oncotarget · doi:10.18632/oncotarget.13668 · Cited by 54
Fan, H., Wang, X., Li, W., Shen, M., Wei, Y., Zheng, H., & Kang, Y. (2020) · Genes & Development · doi:10.1101/gad.339796.120 · Cited by 54
Hyun, J., Abo, M. A., Dutta, R. K., Oh, S., Xiang, K., Zhou, X., Maeso‐Díaz, R., Caffrey, R., Sanyal, A. J., Freedman, J. A., et al. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2021.04.033 · Cited by 54
Murphy, K. J., Reed, D. A., Vennin, C., Conway, J. R. W., Nobis, M., Yin, J. X. M., Chambers, C. R., Pereira, B., Lee, V., Filipe, E. C., et al. (2021) · Science Advances · doi:10.1126/sciadv.abh0363 · Cited by 54
Mst1 overexpression inhibited the growth of human non-small cell lung cancer in vitro and in vivo
Xu, C., Liu, W. W., Liu, C. J., Wen, C., Lü, H., & Wan, F. (2013) · Cancer Gene Therapy · doi:10.1038/cgt.2013.40 · Cited by 52
Targeting loss of the Hippo signaling pathway in NF2-deficient papillary kidney cancers
Sourbier, C., Liao, P., Ricketts, C. J., Wei, D., Yang, Y., Baranes, S. M., Gibbs, B. K., Ohanjanian, L., Krane, L. S., Scroggins, B. T., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.24112 · Cited by 52
Liu, J., Gao, M., NIPPER, M. J., Deng, J., Sharkey, F. E., Johnson, R. L., Crawford, H. C., Chen, Y., & Wang, P. (2019) · PLoS Biology · doi:10.1371/journal.pbio.3000418 · Cited by 51
Mechanical force regulation of YAP by F-actin and GPCR revealed by super-resolution imaging
Gao, J., He, L., Zhou, L., Jing, Y., Wang, F., Shi, Y. C., Cai, M., Sun, J., Xu, H., Jiang, J., et al. (2020) · Nanoscale · doi:10.1039/c9nr09452k · Cited by 50
Discovery of a subtype-selective, covalent inhibitor against palmitoylation pocket of TEAD3
Lu, T., Li, Y., Lu, W., Spitters, T., Fang, X., Wang, J., Cai, S., Gao, J., Zhou, Y., Duan, Z., et al. (2021) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.04.015 · Cited by 50
Basu-Roy, U., Han, E. J., Rattanakorn, K., Gadi, A., Verma, N., Maurizi, G., Gunaratne, P. H., Coarfa, C., Kennedy, O. D., Garabedian, M. J., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.11273 · Cited by 49
de Lange, M. J., Razzaq, L., Versluis, M., Verlinde, S., Doğrusöz, M., Böhringer, S., Marinkovic, M., Luyten, G. P. M., de Keizer, R. J. W., de Gruijl, F. R., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0138002 · Cited by 48
Yap regulates skeletal muscle fatty acid oxidation and adiposity in metabolic disease
Watt, K. I., Henstridge, D. C., Ziemann, M., Sim, C. B., Montgomery, M. K., Samocha‐Bonet, D., Parker, B. L., Dodd, G. T., Bond, S. T., Salmi, T. M., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-23240-7 · Cited by 48
Cheng, S., Prieto‐Domínguez, N., Yang, S., Connelly, Z. M., StPierre, S., Rushing, B., Watkins, A., Shi, L., Lakey, M. A., Baiamonte, L. B., et al. (2020) · Prostate Cancer and Prostatic Diseases · doi:10.1038/s41391-020-0229-z · Cited by 47
Zhu, M. L., Peng, R., Liang, X., Lan, Z., Tang, M., Hou, P., Song, J. H., Mak, C. S. L., Park, J., Zheng, S.-E., et al. (2021) · Oncogene · doi:10.1038/s41388-021-02000-3 · Cited by 47
Santoro, R., Zanotto, M., Carbone, C., Piro, G., Tortora, G., & Melisi, D. (2018) · Anticancer Research · doi:10.21873/anticanres.12431 · Cited by 46
Targeted molecular profiling reveals genetic heterogeneity of poromas and porocarcinomas
Bosić, M., Kirchner, M., Brasanac, D. C., et al. (2017) · Pathology · doi:10.1016/j.pathol.2017.10.011 · Cited by 45
Discovery of recurrent structural variants in nasopharyngeal carcinomaPreprint
Valouev, A., Weng, Z., Sweeney, R. T., Varma, S., Le, Q., Kong, C. S., Sidow, A., & West, R. B. (2013) · Genome Research · doi:10.1101/gr.156224.113 · Cited by 44
Hippo Reprograms the Transcriptional Response to Ras Signaling
Pascual, J., Jacobs, J., Sansores-García, L., Natarajan, M., Zeitlinger, J., Aerts, S., Halder, G. A., & Hamaratoǧlu, F. (2017) · Developmental Cell · doi:10.1016/j.devcel.2017.08.013 · Cited by 44
Morice, S., Mullard, M., Brion, R., Dupuy, M., Renault, S., Tesfaye, R. A., Royer, B. B.-L., Ory, B., Rédiní, F., & Verrecchia, F. (2020) · Cancers · doi:10.3390/cancers12123847 · Cited by 44
Hypoxic conditions differentially regulate TAZ and YAP in cancer cells
Yan, L., Cai, Q., & Xu, Y. (2014) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2014.07.024 · Cited by 43
Targeting Hippo coactivator YAP1 through BET bromodomain inhibition in esophageal adenocarcinoma
Song, S., Li, Y., Xu, Y., Ma, L., Pizzi, M. P., Jin, J., Scott, A. W., Huo, L., Wang, Y., Lee, J. H., et al. (2020) · Molecular Oncology · doi:10.1002/1878-0261.12667 · Cited by 43
STK25 suppresses Hippo signaling by regulating SAV1-STRIPAK antagonism
Bae, S. J., Ni, L., & Luo, X. (2020) · eLife · doi:10.7554/elife.54863 · Cited by 43
YAP1/TAZ drives ependymoma-like tumour formation in mice
Eder, N., Roncaroli, F., Domart, M., Horswell, S. D., Andreiuolo, F. D. M., Flynn, H. R., Lopes, A. T., Claxton, S., Kilday, J., Collinson, L., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-16167-y · Cited by 43
Yang, H., Hall, S. R. R., Sun, B., Zhao, L., Gao, Y., Schmid, R. A., Tan, S. T., Peng, R., & Yao, F. (2021) · Cancers · doi:10.3390/cancers13071561 · Cited by 43
Lamar, J. M., Nehru, V. M., & Weinberg, G. L. (2018) · Cancers · doi:10.3390/cancers10070229 · Cited by 42
Csako, G., McGriff, N. J., Rotman-Pikielny, P., Sarlis, N. J., & Pucino, F. (2001) · Annals of Pharmacotherapy · doi:10.1345/aph.1a031 · Cited by 40
Kim, J., Kang, D., Long, L. Z., Huang, S.-M., Yeo, M., Yi, E. S., & Kim, K. (2010) · Human Pathology · doi:10.1016/j.humpath.2010.08.003 · Cited by 39
YAP ping about and not forgetting TAZ
Callus, B. A., Finch‐Edmondson, M., Fletcher, S., & Wilton, S. D. (2018) · FEBS Letters · doi:10.1002/1873-3468.13318 · Cited by 37
Kim, D. K., Kim, E. K., Jung, D., & Kim, J. (2019) · PLoS ONE · doi:10.1371/journal.pone.0214553 · Cited by 35
Unintended Effects of GPCR-Targeted Drugs on the Cancer Phenotype
Cornwell, A. C., & Feigin, M. E. (2020) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2020.10.001 · Cited by 34
Bokhovchuk, F. M., Mesrouze, Y., Izaac, A., Meyerhofer, M., Zimmermann, C., Fontana, P., Schmelzle, T., Erdmann, D., Furet, P., Kallen, J. A., et al. (2019) · FEBS Journal · doi:10.1111/febs.14817 · Cited by 32
Raimondi, F., Inoue, A., Kadji, F. M. N., Ni, S., González‐Sánchez, J. C., Singh, G., de la Vega, A. A., Sotillo, R., Fischer, B., Aoki, J., et al. (2019) · Oncogene · doi:10.1038/s41388-019-0895-2 · Cited by 30
Regué, L., Mou, F., & Avruch, J. (2013) · BioEssays · doi:10.1002/bies.201200163 · Cited by 29
TEAD2 as a novel prognostic factor for hepatocellular carcinoma
Joo, J., Cho, S., Rou, W. S., Kim, J., Kang, S. H., Lee, E. S., Moon, H. S., Kim, S., Sung, J., Kwon, I. S., et al. (2020) · Oncology Reports · doi:10.3892/or.2020.7578 · Cited by 26
Splice variant insertions in the C-terminus impairs YAP’s transactivation domain
Finch‐Edmondson, M., Strauss, R. P., Clayton, J. S., Yeoh, G. C., & Callus, B. A. (2016) · Biochemistry and Biophysics Reports · doi:10.1016/j.bbrep.2016.02.015 · Cited by 21
Park, J., Kim, J. S., Nahm, J. H., Kim, S. K., Lee, D.-H., & Lim, D. (2020) · PubMed Central · doi:10.14348/molcells.2020.0093 · Cited by 21
Zhang, N., Zhang, Z., Long, J., Li, H., Zhang, B., Chen, G., Li, X., Lv, T., Zhang, W., Ou, X., et al. (2017) · Oncology Reports · doi:10.3892/or.2017.6055 · Cited by 20
An alternatively transcribed TAZ variant negatively regulates JAK‐STAT signaling
Fang, C., Li, J., Qi, S., Lei, Y., Zeng, Y. J., Yu, P., Hu, Z., Zhou, Y., Wang, Y., Dai, R., et al. (2019) · EMBO Reports · doi:10.15252/embr.201847227 · Cited by 20
Jong, C. J., Merrill, R. A., Wilkerson, E., Herring, L. E., Graves, L. M., & Strack, S. (2020) · Journal of Biological Chemistry · doi:10.1074/jbc.ra119.011270 · Cited by 19
Cellular feedback dynamics and multilevel regulation driven by the hippo pathway
Park, J., & Hansen, C. G. (2021) · Biochemical Society Transactions · doi:10.1042/bst20200253 · Cited by 19
Self-citationMutational analysis of tumour suppressor gene NF2 in common solid cancers and acute leukaemias
Yoo, N. J., Park, S. W., & Lee, S. H. (2011) · Pathology · doi:10.1097/pat.0b013e32834c3599 · Cited by 18
Singh, K., Pruski, M. A., Polireddy, K., Jones, N. C., Chen, Q., Yao, J., Dar, W. A., McAllister, F. M., Ju, C., Eltzschig, H. K., et al. (2019) · Oncogene · doi:10.1038/s41388-019-1031-z · Cited by 18
Cysteine residues are essential for dimerization of Hippo pathway components YAP2L and TAZ
Khanal, P., Jia, Z., & Yang, X. (2018) · Scientific Reports · doi:10.1038/s41598-018-21828-6 · Cited by 16
Control of Tissue Growth and Cell Transformation by the Salvador/Warts/Hippo Pathway
Zhang, X., Grusche, F., & Harvey, K. F. (2012) · PLoS ONE · doi:10.1371/journal.pone.0031994 · Cited by 15
TEAD–YAP Interaction Inhibitors and MDM2 Binders from DNA‐Encoded Indole‐Focused Ugi Peptidomimetics
Kunig, V. B. K., Potowski, M., Akbarzadeh, M., Škopić, M. K., Smith, D. D. S., Arendt, L., Dormuth, I., Adihou, H., Andlovic, B., Karataş, H., et al. (2020) · Angewandte Chemie · doi:10.1002/ange.202006280 · Cited by 13
Brandt, Z. J., Echert, A. E., Bostrom, J. R., North, P. N., & Link, B. A. (2020) · Development · doi:10.1242/dev.184242 · Cited by 9
One Metformin a Day, Keeps Lung Cancer Away! Or Does It?
Shojaee, S., & Nana-Sinkam, P. S. (2020) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2020.10.005 · Cited by 1
Research works printed but not linked: 12
- Evans, 2009, Neurofibromatosis 2 [Bilateral acoustic neurofibromatosis, central neurofibromatosis, NF2, neurofibromatosis type II], Genet. Med., 11, 599, 10.1097/GIM.0b013e3181ac9a27 · doi:10.1097/gim.0b013e3181ac9a27
- Begnami, 2007, Evaluation of NF2 gene deletion in sporadic schwannomas, meningiomas, and ependymomas by chromogenic in situ hybridization, Hum. Pathol., 38, 1345, 10.1016/j.humpath.2007.01.027 · doi:10.1016/j.humpath.2007.01.027
- Yakirevich, 2020, NF2 mutation-driven renal cell carcinomas (RCC): a comprehensive genomic profiling (CGP) study, J. Clin. Oncol., 38, 726, 10.1200/JCO.2020.38.6_suppl.726 · doi:10.1200/jco.2020.38.6_suppl.726
- Zhao, 2007, Inactivation of YAP oncoprotein by the Hippo pathway is involved in cell contact inhibition and tissue growth control, Genes Dev., 21, 2747, 10.1101/gad.1602907 · DOI · Paper page
- Lee, 2016, Epithelioid hemangioendotheliomas with TFE3 gene translocations are compossible with CAMTA1 gene rearrangements, Oncotarget, 7, 7480, 10.18632/oncotarget.7060 · doi:10.18632/oncotarget.7060
- Russell-Goldman, 2021, Utility of YAP1 and NUT immunohistochemistry in the diagnosis of porocarcinoma, J. Cutan. Pathol., 48, 403, 10.1111/cup.13924 · doi:10.1111/cup.13924
- Nishimura, 2021, Cutaneous primary NUT carcinoma with BRD3-NUTM1 fusion, Am. J. Surg. Pathol., 45, 1582, 10.1097/PAS.0000000000001801 · doi:10.1097/pas.0000000000001801
- Pei, 2015, YAP is a critical oncogene in human cholangiocarcinoma, Oncotarget, 6, 17206, 10.18632/oncotarget.4043 · DOI
- Carter, 1994, Loss of heterozygosity at 11q22-q23 in breast cancer, Cancer Res., 54, 6270
- Messmer, 2001, Verteporfin for age-related macular degeneration, Ann. Pharmacother., 35, 1593, 10.1345/aph.10365 · doi:10.1345/aph.10365 · Paper page
- Taniguchi, 2015, A gp130-Src-YAP module links inflammation to epithelial regeneration, Nature, 519, 57, 10.1038/nature14228 · DOI · Paper page
- Whitehouse, 2005, Drugs to treat inflammation: a historical introduction, Curr. Med. Chem., 12, 2931, 10.2174/092986705774462879 · doi:10.2174/092986705774462879
Cited by
Insights into recent findings and clinical application of YAP and TAZ in cancer
Franklin, J. M., Wu, Z., & Guan, K.-L. (2023) · Nature Reviews Cancer · doi:10.1038/s41568-023-00579-1 · Cited by 213
Therapeutic targeting of TEAD transcription factors in cancer
Pobbati, A. V., Kumar, R., Rubin, B. P., & Hong, W. (2023) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2022.12.005 · Cited by 147
Metadata
- Authors
- Cunningham, R., & Hansen, C. G.
- Venue
- Clinical Science
- Publisher
- Portland Press Ltd.
- Published
- 2022-02
- Volume
- 136
- Issue
- 3
- Pages
- 197-222
- ISSN
- 0143-5221 (ISSN-L)
- 1470-8736
- OpenAlex
- W4210383344
- Cited by
- 326
- References
- 316
- FWCI
- 29.02
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.